Credits Available: 4.25 AMA PRA Category 1 Credit™; ABIM MOC

Description: Rigorous clinical research has led to the discovery of novel immunologic therapies. Chimeric antigen receptor T cell (CAR T-cell) therapy has shown impressive outcomes but is associated with a significant risk of adverse events (AEs), chiefly cytokine release syndrome (CRS). Bispecific antibodies act through a similar mechanism of action but offer a lower risk of CRS. These AEs may require immediate management, which may occur in the emergency department (ED) setting.

Given the novelty and specialty nature of bispecific antibody and CAR T-cell therapies, ED clinicians face several challenges in the practical management of patients receiving these therapies. Similarly, given the breadth of conditions treated with these therapies, ED clinicians may face difficulties knowing which patient populations are at risk. While CAR T therapies are approved for hematologic malignancies, bispecific antibodies are approved for many indications including hematologic malignancies, non-small cell lung cancer, uveal melanoma, hemophilia A, and neovascular macular edema. This collaborative social learning platform establishes a network of providers who can create a sustainable network of providers who can continue to support each other following this experience in implementing their practice action plans aimed at improving the care provided to patients on CAR T or bispecific therapies.

John Hopkins Medicine Logo

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Associate/Assistant
Target Specialties: Emergency Medicine, Oncology
Group Leader

Richa Thakur

Fred Hutchinson Cancer Center
Oncologist

I am an Oncologist specializing in Multiple Myeloma as well as other plasma cell dyscrasias. I also have a special interest in Palliative Care.

 

Group Co-Leader

Kevin Wang

Northwell Health
Fellow

Hematology oncology fellow with interests in general hematology oncology. Passionate about education and research.